{"id":409380,"date":"2021-01-06T08:03:30","date_gmt":"2021-01-06T13:03:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409380"},"modified":"2021-01-06T08:03:30","modified_gmt":"2021-01-06T13:03:30","slug":"akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/","title":{"rendered":"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span><\/span>\n      <\/p>\n<p>\n        <span><br \/>\n          <span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><br \/>\n        <\/span>, <span class=\"xn-chron\">Jan. 6, 2021<\/span> \/PRNewswire\/ &#8212; <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026829-1&amp;h=523489517&amp;u=http%3A%2F%2Fwww.akebia.com%2F&amp;a=Akebia+Therapeutics%2C+Inc.\" rel=\"nofollow noopener noreferrer\">Akebia Therapeutics, Inc.<\/a> (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that <span class=\"xn-person\">John P. Butler<\/span>, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually <span class=\"xn-chron\">January 11<\/span> \u2013 14, 2021.\u00a0 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg\" title=\"Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto\/Akebia Therapeutics, Inc.)\" alt=\"Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto\/Akebia Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <span>The recorded presentation will be available on the Investors section of the Company&#8217;s website at <\/span><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3026829-1&amp;h=3099928217&amp;u=https%3A%2F%2Fir.akebia.com%2F&amp;a=https%3A%2F%2Fir.akebia.com\" rel=\"nofollow noopener noreferrer\"><br \/>\n          <span>https:\/\/ir.akebia.com<\/span><br \/>\n        <\/a><br \/>\n        <span> beginning <span class=\"xn-chron\">Monday, January 11<\/span>. <\/span>\n      <\/p>\n<p>\n        <b><br \/>\n          <span>About Akebia Therapeutics<br \/><\/span><br \/>\n        <\/b><br \/>\n        <span>Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in <span class=\"xn-location\">Cambridge, Massachusetts<\/span>. For more information, please visit our website at <a href=\"http:\/\/www.akebia.com\" rel=\"nofollow\">www.akebia.com<\/a>, which does not form a part of this release.<\/span>\n      <\/p>\n<p>\n        <b><br \/>\n          <span>Akebia Therapeutics Contact<br \/><\/span><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-person\">Kristen K. Sheppard, Esq.<\/span><br \/>\n          <br \/>\n        <\/span><br \/>\n        <a target=\"_blank\" href=\"mailto:ir@akebia.com\" rel=\"nofollow noopener noreferrer\"><br \/>\n          <span>ir@akebia.com<\/span><br \/>\n        <\/a>\n      <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE38120&amp;sd=2021-01-06\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-2021-conference-301201492.html\">http:\/\/www.prnewswire.com\/news-releases\/akebia-therapeutics-to-present-at-hc-wainwright-bioconnect-2021-conference-301201492.html<\/a><\/p>\n<p>SOURCE  Akebia Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE38120&amp;Transmission_Id=202101060800PR_NEWS_USPR_____NE38120&amp;DateId=20210106\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2021 \/PRNewswire\/ &#8212; Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 \u2013 14, 2021.\u00a0 The recorded presentation will be available on the Investors section of the Company&#8217;s website at https:\/\/ir.akebia.com beginning Monday, January 11. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409380","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2021 \/PRNewswire\/ &#8212; Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 \u2013 14, 2021.\u00a0 The recorded presentation will be available on the Investors section of the Company&#8217;s website at https:\/\/ir.akebia.com beginning Monday, January 11. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, &hellip; Continue reading &quot;Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T13:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference\",\"datePublished\":\"2021-01-06T13:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/\"},\"wordCount\":172,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/\",\"name\":\"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"datePublished\":\"2021-01-06T13:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/","og_locale":"en_US","og_type":"article","og_title":"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass. , Jan. 6, 2021 \/PRNewswire\/ &#8212; Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference, which takes place virtually January 11 \u2013 14, 2021.\u00a0 The recorded presentation will be available on the Investors section of the Company&#8217;s website at https:\/\/ir.akebia.com beginning Monday, January 11. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, &hellip; Continue reading \"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T13:03:30+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference","datePublished":"2021-01-06T13:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/"},"wordCount":172,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/","name":"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","datePublished":"2021-01-06T13:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-present-at-h-c-wainwright-bioconnect-2021-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409380"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409380\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}